Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19--Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance--VISION Network, 10 States, August 2021-January 2022

Authors :: Thompson, Mark G.
Natarajan, Karthik
Irving, Stephanie A.
Rowley, Elizabeth A.
Griggs, Eric P.
Gaglani, Manjusha
Klein, Nicola P.
Grannis, Shaun J.
DeSilva, Malini B.
Stenehjem, Edward
Reese, Sarah E.
Dickerson, Monica
Naleway, Allison L.
Han, Jungmi
Konatham, Deepika
McEvoy, Charlene
Rao, Suchitra
Dixon, Brian E.
Dascomb, Kristin
Lewis, Ned
Levy, Matthew E.
Patel, Palak
Liao, I-Chia
Kharbanda, Anupam B.
Barron, Michelle A.
Fadel, William F.
Grisel, Nancy
Goddard, Kristin
Yang, Duck-Hye
Wondimu, Mehiret H.
Murthy, Kempapura
Valvi, Nimish R.
Arndorfer, Julie
Fireman, Bruce
Dunne, Margaret M.
Embi, Peter
Azziz-Baumgartner, Eduardo
Zerbo, Ousseny
Bozio, Catherine H.
Reynolds, Sue
Ferdinands, Jill
Williams, Jeremiah
Link-Gelles, Ruth
Schrag, Stephanie J.
Verani, Jennifer R.
Ball, Sarah
Ong, Toan C.
Source :: Morbidity and Mortality Weekly Report. January 28, 2022, Vol. 71 Issue 4, p139, 7 p.
Publication Year :: 2022
Abstract: On January 21, 2022, this report was posted as an MMWR Early Release on the MMWR website (https://www.cdc.gov/mmwr). Estimates of COVID-19 mRNA vaccine effectiveness (VE) have declined in recent months [...]

Subjects :: Pfizer Inc.
Medical research
Medicine, Experimental
Hospitals -- Emergency service
Messenger RNA
Emergency medicine
Adults
Vaccines
Pharmaceutical industry
Health
University of Colorado
Comirnaty (Vaccine)

Tools